Zentalis presents preclinical data on azenosertib at AACR cancer research conference

Filed April 17, 2026 · Period ending April 17, 2026 · ~1 min read

Key Changes

• medium

  Company issued press release and presented two research posters at the American Association for Cancer Research Annual Meeting in San Diego, April 17-22, 2026.

  Item 7.01 verify on EDGAR →
• medium

  Preclinical poster evaluated azenosertib, a WEE1 inhibitor, as single agent and in combination for triple-negative breast cancer treatment.

  Exhibit 99.2 view on EDGAR →
• low

  Second poster presented real-world treatment patterns and outcomes for patients with cyclin E1-positive ovarian cancer, a biomarker relevant to Zentalis's therapeutic focus.

  Exhibit 99.3 view on EDGAR →